Neuraptive Therapeutics
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2 Logan Sq Ste 1930, Philadelphia, Penns...Phone Number
(484) 787-3203Website
www.neuraptive.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Neuraptive Therapeutics
Neuraptive is focused on developing innovative therapeutics and medical products to meet the needs of physicians and patients affected by peripheral nerve injuries. Their offerings include a novel fusion system for repairing severed peripheral nerves, a specialized drug delivery device for topical administration, and nerve-specific microsurgical instruments. The company aims to address a significant market opportunity of $2.7 billion in the U.S. and $5.5 billion globally, targeting acute trauma patients and those undergoing corrective surgeries. Neuraptive's products are designed to improve the speed and outcomes of nerve repair procedures.Explore more
Neuraptive Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neuraptive Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Neuraptive Therapeutics
Check if Neuraptive Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Neuraptive Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Neuraptive Therapeutics has new funding data
Product Launch: Get notified when Neuraptive Therapeutics launches new products
Neuraptive Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Neuraptive Therapeutics is spiking on competitors!
Earning: See what the market has to say on Neuraptive Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Neuraptive Therapeutics
Find 2 more new buyers
Compare Similar Companies to Neuraptive Therapeutics
Compare insights from companies similar to Neuraptive Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Neuraptive Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neuraptive Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neuraptive Therapeutics.
Neuraptive Therapeutics financials insights
Gather financial insights about Neuraptive Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Angel/Seed
$1M
2018
Series A
$11.5M
2021
Debt
$153K
2022
Private Equity
$7.5M
Neuraptive Therapeutics Tech Stack
A closer look at the technologies used by Neuraptive Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Board of Directors
Funding
New Hire
Executive Move
Neuraptive Therapeutics News & Media
Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair
CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair. This designation follows the results from the Phase 2 NEUROFUSE study and several interactions with the FDA. NTX-001 has the potential to be a groundbreaking therapy in the field of nerve repair. Neuraptive is preparing to launch a PhasNeuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
WAYNE, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a pioneer in nerve repair and regeneration, is proud to announce new 24-week data from the ongoing NEUROFUSE Study for NTX-001, further solidifying the product's status following the previously announced proof of concept results based on the 12-week data in January 2024. The latest data from the multicenter, randomized, evaluator-blinded, Phase 2a NEUROFUSE Study underscores NTX-001’s sustained safety and efficacy as an adjunct treatmeNeuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset
WAYNE, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the United States (US) Food and Drug Administration (FDA) for its fusogen contained in the NTX-001 treatment kit. This designation marks a significant milestone in developing NTX-001, a novel treatment for peripheral nerve injury requiring repair. Dr. Seth Schulman, Chief Medical Officer of Neuraptive Therapeutics Inc., staNeuraptive Therapeutics, Inc. Strengthens its Board of Directors With Appointment of Cary Sucoff, J.D.
PHILADELPHIA--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announces the appointment of Cary Sucoff, J.D. to the company’s Board of Directors. “On behalf of the Neuraptive Board and its directors, we are excited to welcome Cary to the board,” said Robert Radie, chairman, and chief executive officer of Neuraptive.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neuraptive Therapeutics
Sign Up For FreeTo access detailed company insights
Neuraptive is focused on developing innovative therapeutics and medical products to meet the needs of physicians and patients affected by peripheral nerve injuries. Their offerings include a novel fusion system for repairing severed peripheral nerves, a specialized drug delivery device for topical administration, and nerve-specific microsurgical in... Read More
